Immunomedics Incorporated (NASDAQ:IMMU) Shorted Shares Increased 0.62% After Market Selling

October 2, 2017 - By Nellie Frank

 Immunomedics Incorporated (NASDAQ:IMMU) Shorted Shares Increased 0.62% After Market Selling

Investors sentiment decreased to 1.41 in Q2 2017. Its down 0.05, from 1.46 in 2017Q1. It is negative, as 24 investors sold Immunomedics, Inc. shares while 30 reduced holdings. 30 funds opened positions while 46 raised stakes. 83.89 million shares or 25.65% more from 66.77 million shares in 2017Q1 were reported.
Bank Of Montreal Can stated it has 0% in Immunomedics, Inc. (NASDAQ:IMMU). Ameriprise Fincl has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Tower Cap Ltd Com (Trc) owns 775 shares or 0% of their US portfolio. Morgan Stanley owns 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 195,391 shares. Financial Bank Of New York Mellon reported 628,135 shares stake. First Light Asset Limited Company reported 2.05M shares. Price T Rowe Associate Md reported 5.97M shares or 0.01% of all its holdings. Spark Management Ltd Limited Liability Company stated it has 0.04% in Immunomedics, Inc. (NASDAQ:IMMU). Knott David M reported 0.24% stake. Blackrock stated it has 0% in Immunomedics, Inc. (NASDAQ:IMMU). Millennium Mgmt Ltd Llc reported 4.22 million shares stake. Css Ltd Il holds 0% or 4,734 shares. Great West Life Assurance Can has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU). Vanguard has 4.52M shares. Metropolitan Life Insurance has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU).

The stock of Immunomedics Incorporated (NASDAQ:IMMU) registered an increase of 0.62% in short interest. IMMU’s total short interest was 34.29 million shares in October as published by FINRA. Its up 0.62% from 34.07M shares, reported previously. With 4.66M shares average volume, it will take short sellers 7 days to cover their IMMU’s short positions. The short interest to Immunomedics Incorporated’s float is 38.33%.

The stock increased 1.90% or $0.26 on September 29, reaching $13.98. About shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since October 2, 2016 and is uptrending. It has outperformed by 59.56% the S&P500.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.75 billion. The Firm is engaged in developing monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. It currently has negative earnings. The Company’s geographic divisions include United States and Europe.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 12 analyst reports since July 29, 2015 according to SRatingsIntel. As per Friday, December 4, the company rating was downgraded by Wells Fargo. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) on Thursday, August 17 with “Buy” rating. The company was downgraded on Wednesday, July 29 by Jefferies. The rating was maintained by Cowen & Co with “Buy” on Monday, July 24. The stock has “Buy” rating by Jefferies on Tuesday, September 19. Jefferies reinitiated Immunomedics, Inc. (NASDAQ:IMMU) on Thursday, October 6 with “Buy” rating. The company was maintained on Friday, June 9 by Jefferies. The stock has “Market Perform” rating by Wells Fargo on Tuesday, June 21. Cowen & Co maintained the shares of IMMU in report on Wednesday, August 16 with “Buy” rating. The stock has “Hold” rating by Jefferies on Tuesday, March 15.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com